A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters by M Nelida Fernandez-Martinez et al.
Fernandez-Martinez et al. BMC Complementary and Alternative Medicine 2014, 14:296
http://www.biomedcentral.com/1472-6882/14/296RESEARCH ARTICLE Open AccessA randomised clinical trial to evaluate the effects
of Plantago ovata husk in Parkinson patients:
changes in levodopa pharmacokinetics and
biochemical parameters
M Nelida Fernandez-Martinez1*†, Luis Hernandez-Echevarria2†, Matilde Sierra-Vega1†, M Jose Diez-Liebana1†,
Angela Calle-Pardo1†, Demetrio Carriedo-Ule2†, Ana M Sahagún-Prieto1†, Anna Anguera-Vila3
and Juan Jose Garcia-Vieitez1†Abstract
Background: Plantago ovata husk therapy could be used in patients with Parkinson disease to reduce the
symptoms of gastrointestinal disorders, but it is important to know whether this compound modifies levodopa
pharmacokinetics. The maintenance of constant plasma concentrations of levodopa abolishes the clinical
fluctuations in parkinsonian patients. The aim of this randomised clinical trial was to establish the influence of the
fiber Plantago ovata husk in the pharmacokinetics of levodopa when administered to Parkinson patients well
controlled by their oral medication.
Methods: To evaluate the effects of this fiber on several biochemical parameters. 18 volunteers participated in
the study and received alternatively two treatments (Plantago ovata husk or placebo) with their usual
levodopa/carbidopa oral dose. On days 0 (initial situation), 14 and 35 of the study, blood samples were taken to
assess levodopa pharmacokinetics and to determine biochemical parameters.
Results: Levodopa Cmax was very similar in the initial situation (603.2 ng/ml) and after placebo administration
(612.0 ng/ml), being slightly lower (547.8 ng/ml) when Plantago ovata husk was given. AUC was very similar in
the three groups: initial situation.- 62.87 μg.min/ml, fiber treatment.- 64.47 μg.min/ml and placebo treatment.- 65.10
μg.min/ml. Fiber reduced significantly the number of peaks observed in the levodopa concentrations, maintaining
concentrations more stable. No significant differences were found in total cholesterol, LDL-cholesterol and triglycerides
with the administration of Plantago ovata husk.
Conclusions: Plantago ovata husk administration caused a smoothing and homogenization of levodopa absorption,
providing more stable concentrations and final higher levels, resulting in a great benefit for patients.
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Parkinson’s disease remains one of the most common
neurodegenerative diseases, affecting 1% of the popula-
tion over 65 [1]. Autonomic disorders are often seen in
idiopathic Parkinson, especially in the advanced stage of
the disease. Disturbances of the gastrointestinal tract are
considered to be the most frequent autonomic disorders,
including abnormal salivation, difficulty of swallowing
(dysphagia), early feeling of satiety (abdominal bloating-
distension), disorders of gastric emptying and constipa-
tion [2-4]. These symptoms may affect the quality of life
of Parkinson’s patients.
Constipation has been reported in over 50% of patients
with Parkinson’s disease attending a movement disorders
clinic [2]. In the elderly, constipation may correlate with
decreased physical activity, a low fluid intake, a diet poor
in fiber, the sedentary life style and also to the illness it-
self [5]. Prokinectic drugs may help reduce the symp-
toms of gastrointestinal dismotility, but the side effects
preclude their prolonged use [6].
Plantago ovata husk (ispaghula husk) is a viscous water-
soluble fiber that has been used as a bulk laxative with a
good safety record. This fiber could be a good alternative
to help to solve constipation problems in patients with
Parkinson’s disease. However, it is important to know
whether this compound modifies levodopa pharmacokin-
etics. Fiber can retain a part of the dose administered; it
also can modify gastric emptying as well as the absorption
conditions in the small bowel and the presystemic clear-
ance of the drug.
The influence of Plantago ovata husk on levodopa
pharmacokinetics could be clinically relevant due to the
special kinetic features of this antiparkinsonian drug.
Levodopa has a peculiar pharmacokinetics, charac-
terised by an extensive presystemic metabolism, a rapid
absorption in the proximal small intestine and a very
short plasma half-life due to its rapid metabolism [7].
Maintenance of constant plasma concentrations of
levodopa largely abolishes the clinical fluctuations in
parkinsonian patients [7-10], indicating that delivery of
levodopa to the striatum is a critical determinant of clin-
ical response [11].
Dietary factors can modify the rate and extent of levo-
dopa absorption. It is well established, for example, that
its absorption can be reduced or retarded by concomi-
tant food intake [12,13]. On the other hand, aromatic
and branched chain amino acids of concomitant protein
rich meals may compete with levodopa for the carrier
system across the intestinal mucosa, directly affecting
levodopa absorption [14].
Therefore, an understanding of the pharmacokinetics
of any drug is crucial for the establishment of its optimal
therapeutic regimen. This assumes a special importance
with levodopa [14].The aim of the present study was to establish the in-
fluence of the fiber Plantago ovata husk (that provides
the aqueous solution a high viscosity) in the pharmaco-
kinetics of levodopa when administered to Parkinson pa-
tients well controlled by their oral medication. We also
evaluated the effects of this fiber on several biochemical
parameters such as glucose, cholesterol, uric acid, etc.
Methods
Patients and treatment
The study carried out was a prospective, aleatory crossed
and double-blind randomised clinical trial (EudraCT2006-
000491-33; clinicaltrials.gov/ct2/show/NCT00507715).
We studied 18 patients (10 men, 8 women) with idiopatic
Parkinson disease attending the Neurology Service of the
Hospital Universitario de Leon, Spain, whose sympthoms
were controlled by levodopa/carbidopa oral medication.
The recruitment of participants took place between April
and May 2006, and the trial developed between September
and November 2006.
Inclusion criteria were: (a) patients with idiopathic
Parkinson disease whose sympthoms were controlled by
levodopa/carbidopa oral medication; (b) at least 3 months
of levodopa treatment; (c) between 60 and 80 years of age.
Exclusion criteria were: (a) patients participating in other
clinical trial or that have participated in the last month;
(b) allergy or contraindication to Plantago ovata husk;
(c) chronic renal failure or hepatic disorders; (d) psy-
chiatric disorders; (e) patients with diabetes mellitus or in
treatment with oral hypoglcemic agents.
The study was approved by the Ethical Committee of
the Hospital de León as well as the Spanish Medicines
Agency (AEMPS). All participants provided written in-
formed consent prior to enrolment into the trial. At the
time of examination, the mean age was 69.8 ± 4.2 years,
the mean disease duration was 1.3 ± 0.5 years, and the
mean duration of levodopa treatment was 0.7 ± 0.5 years.
Volunteers were randomly divided into two groups of
9 patients each (Table 1). Both groups received alterna-
tively two treatments according to the diagram included
in Figure 1: treatment A, administration of Plantago
ovata husk; and treatment B, administration of placebo.
To generate the random allocation, a numbered list of
the participants was created and an Excell aleatory num-
ber generator was used.
During treatment A (Plantago ovata husk administra-
tion), volunteers received their usual levodopa/carbidopa
oral dose (100/25 mg), (Sinemet®, MSD) three times a
day and, immediately before, 3.5 g Plantago ovata husk
(Plantaben®, Rottapharm S.L., Barcelona, Spain) dispersed
into 200 ml water. Plantago ovata husk was manufactured
as a palatable, orange-flavoured, sugar-free product, dis-
tributed in sachets of 5 g each, containing 3.5g of Plantago
ovata husk. The other 9 patients (treatment B) received






Sex (Men/Women) (5/4) (5/4)
Age (Mean ± SD) (years) 68.7 ± 3.1 70.3 ± 4.3
Disease duration (Mean ± SD) (years) 1.4 ± 0.6 1.3 ± 0.4
Duration of levodopa treatment
(Mean ± SD) (years)
0.7 ± 0.3 0.8 ± 0.5
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ments for 14 days, and after a wash-out period of 7 days,
the other treatment (A or B) was given.
To assess levodopa pharmacokinetics, on days 0, 14
and 35 of the study, volunteers came up to the Neur-
ology Service of the Hospital Universitario de Leon at
8:00 AM following an overnight fast. After taking their
medication, blood samples were obtained through an
intravenous catheter at 0, 10, 20, 30, 45, 60, 90, 120, 180,
240 and 300 min after drug administration. At time 0 an
additional sample was collected to determine biochem-
ical parameters: glucose, triglycerides, total cholesterol,
LDL-cholesterol, HDL-cholesterol, uric acid, creatinin.Figure 1 Flow chart of the study participants.Immediately after blood sample collection, plasma was
separated by centrifugation and stored at –20°C until
analysis.
The results obtained on day 0 (initial situation) served
to asses patients conditions before starting the treatment
with Plantago ovata husk or placebo. At the end of the
visit, the Plantago ovata husk or placebo treatment ne-
cessary for the first 14 days of the study was given to the
volunteers.
On day 14, the patients brought the Plantago ovata
husk or placebo packing (full or empty) given on day 0
to evaluate therapeutic compliance, and received the
Plantago ovata husk or placebo treatment necessary for
the next 14 days of the study (from day 21 to 35, after a
7 days wash-out period). On the final visit (day 35), the
full or empty packing were also collected.Levodopa determination
Levodopa extraction from plasma samples was carried
out by using a catecholamine kit (Chromsystems®) and
was quantified by HPLC with electrochemical detection.
The mobile phase consisted of 50 mM sodium dihydro-
genphosphate buffer adjusted to pH 2.9 with 1 M ortho-
phosphoric acid containing 250 mg/l heptanesulphonic
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mobile phase was pumped at a flow rate of 1 ml/min.
The analytical column was a 25 cm × 4.6 mm I.D.
stainless-steel column, packed with Spherisorb ODS-2
(5 pm particle size, Waters Chromatography SA, Madrid,
Spain) and the potential applied was 500 mV. Interday
and intraday accuracy and precision were within 10%.
Pharmacokinetic studies
Pharmacokinetic analysis was performed based on a
non-compartmental description of the data observed.
Maximum plasma levodopa concentration (Cmax) and
the time to reach maximum concentration (tmax) were
read directly from the individual plasma concentration-
time curves.
The WinNonlin® computer program and formulae de-
scribed by Gibaldi and Perrier [15] were used to calculate
the model-independent pharmacokinetic parameters: the
elimination rate constant (λ), the area under the plasma
concentration-time curve (AUC), the clearance (Cl/F), the
volume of distribution at steady state (Vss/F), the half-life
associated with λ phase (t1/2λ), the area under the first
moment curve (AUMC), and the mean residence time
(MRT).
Levodopa concentration was also determined in the sam-
ple taken at time 0 and it was considered as minimum
plasma levodopa concentration (Cmin). In addition, a quali-
tative pharmacokinetic variable was studied: the number of
peaks observed in the levodopa concentration-time curve.
Statistical evaluation
The following formula was used to estimate the sample
size:
N ¼ 2 Zα þ Zβ
 2⋅ S2 = d2
Calculations were performed using 80% power, a 5%
significance level and a standard deviation/precision ra-
tio of 0,75.
All pharmacokinetic and biochemical parameters were
calculated for each volunteer and presented as arith-
metic mean ± standard deviation (mean ± SD). Data
were analysed using the Skewness test (to determine the
normality) and Cochran test (to determine the uniform-
ity of the variance).
The statistical analysis taking into account subject as a
random effect and the period effect was done. When the
data were normal and there was uniformity in the variance,
analysis of variance (ANOVA with repeated measures) was
carried out and the paired t test was used to determine dif-
ferences between data sets. When the data were not nor-
mal and/or there was not uniformity in the variance,
Friedman test was employed and the Wilcoxon test was
used to determine differences between data sets.To evaluate differences in the number of peaks observed
in the concentration versus time curves (one peak or more
than one peak), Pearson’s Chi-squared was employed, or
Fisher test when the first could not be used. P ≤ 0.05 was
used as the level of significance for all analyses.
Results
All the patients enrolled in the study completed the two
phases of the clinical trial. The median obtained for
therapeutic compliance was 100%, with a minimum of
98% and a maximum of 100%.
The plots of plasma levodopa concentration as a func-
tion of time obtained in each patient for the three treat-
ments studied (initial situation, Plantago ovata husk
treatment and placebo treatment) are shown in Figures 2,
3 and 4.
The non-compartmental pharmacokinetic parameters
obtained after the administration of 100:25 mg/kg levo-
dopa/carbidopa and in the presence of Plantago ovata
husk or placebo are summarized in Table 2.
The values obtained for Cmax were very similar in the
initial situation (603.2 ± 242.4 ng/ml) and after the ad-
ministration of placebo (612.0 ± 176.6 ng/ml). This par-
ameter was slightly lower (547.8 ± 192.6 ng/ml) when
Plantago ovata husk was given, although there were no
significant differences between groups (ANOVA).
Regarding AUC, the mean value determined for this
parameter was very similar in the three groups: 62.87 ±
15.77 μg.min/ml in the initial situation, 64.47 ± 15.27 μg.
min/ml after fiber treatment and 65.10 ± 14.33 μg.min/ml
after placebo treatment.
Levodopa absorption was slightly slower in the pres-
ence of Plantago ovata husk (tmax = 39.72 min) than in
the initial situation (tmax = 35.83 min) or after placebo
administration (tmax = 36.17 min). However, no signifi-
cant differences were found between these values. In
addition, there were no significant differences in any of
the pharmacokinetic parameters studied.
Regarding the number of peaks observed in the levodopa
concentration-time curves, a very important fact was
found. It can be seen (Figures 2, 3 and 4) that there were,
respectively, 8, 2 and 9 patients that showed more than one
peak in the initial situation, after fiber treatment and when
placebo was administered. Statistical analysis revealed that
there were significant differences between treatment with
fiber and the other two groups studied (initial situation and
placebo). So, fiber clearly reduced the number of peaks
maintaining levodopa concentrations more stable.
As we have mentioned, at time 0, an extra sample was
taken to determine biochemical parameters. Table 3 includes
the mean value for these parameters on day 0 (initial situ-
ation) and after fiber or placebo treatment.
When fiber was administered, there was a slight reduc-
tion in total cholesterol (191.9 mg/100 ml) in comparison
Figure 2 Levodopa concentrations obtained alter the oral administration of 100:25 mg/kg levodopa/carbidopa in the three groups studied
(initial situation blue triangle; treatment with Plantago ovata husk green circle and treatment with placebo red square) to 18 Parkinson patients.
Volunteers 1 to 6.
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treatment (209.5 mg/100 ml). The mean values for trygli-
cerides and LDL-cholesterol were also lower (10 and 15%,
respectively). However, no significant differences were
found between the three groups studied in any of the bio-
chemical parameters evaluated.
Discussion and conclusions
Levodopa remains to be one of the main drugs in the treat-
ment of Parkinson’s disease. Studies on the concentration-effect relationship of levodopa in Parkinson’s disease have
established that it is beneficial to maintain stable plasma
concentrations of levodopa [7-10].
Several authors have studied the pharmacokinetics of
levodopa in patients with Parkinson’s disease. After the
administration of 100 mg levodopa combined with a dopa
decarboxylase inhibitor, the values obtained for Cmax were
next to 1000 ng/ml [16-18]. In our study, in the initial
situation of patients, the data ranged from 343.1 to 1433.9
ng/ml, so, in some patients the values were similar to that
Figure 3 Levodopa concentrations obtained alter the oral administration of 100:25 mg/kg levodopa/carbidopa in the three groups
studied (initial situation blue triangle; treatment with Plantago ovata husk green circle and treatment with placebo red square) to 18
Parkinson patients. Volunteers 7 to 12.
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lar result was obtained for tmax. This parameter ranged
from 20 to 90 minutes as in other studies [10,17,19]. How-
ever, the mean AUC value (62.87 μg.min/ml) was slightly
lower than that found by other authors using the same
dose of levodopa: 98.9 μg.min/ml [16], 99.7 μg.min/ml
[18], 117.0 μg.min/ml [17].In the present study, we evaluated the influence of
Plantago ovata husk in the pharmacokinetics of levodopa
in well controlled Parkinson patients. The results obtained
showed that after Plantago ovata husk administration no
significant differences were obtained for the pharmacoki-
netic parameters evaluated. However, its absorption
increased slightly, with more stable concentrations and
Figure 4 Levodopa concentrations obtained alter the oral administration of 100:25 mg/kg levodopa/carbidopa in the three groups
studied (initial situation blue triangle; treatment with Plantago ovata husk green circle and treatment with placebo red square) to 18
Parkinson patients. Volunteers 13 to 18.
Fernandez-Martinez et al. BMC Complementary and Alternative Medicine 2014, 14:296 Page 7 of 10
http://www.biomedcentral.com/1472-6882/14/296final higher levels. The lack of significant differences can
be explained by the great differences observed in the phar-
macokinetic behaviour of levodopa in each patient. Due to
this fact, it is very important to evaluate each patient in
separate, and, as the figures show, in most of them, the ad-
ministration of fiber improved the concentration-time
curve for levodopa as well as its pharmacokinetics: thelevels are more stable, with lower maximum concentra-
tions and higher final levels.
Considering the qualitative pharmacokinetic variable
studied: presence of one or more than one peak in the
concentration-time curve, it was clearly demonstrated
that Plantago ovata husk treatment reduced the number
of peaks. Other authors [20-22] also observed the
Table 2 Pharmacokinetic parameters obtained alter the oral administration of 100:25 mg/kg levodopa/carbidopa in
the three groups studied (initial situation; treatment with Plantago ovata husk and treatment with placebo) to 18
Parkinson patients
Initial situation Treatment A (Plantago ovata husk) Treatment B (Placebo)
Parameters Mean ± SD CV(%) Mean ± SD CV(%) Mean ± SD CV(%)
tmax (min) 35.83 ± 16.91 47.20 39.72 ± 17.19 43.28 36.17 ± 26.30 59.56
Cmax (ng/ml) 603.2 ± 242.4 40.19 547.8 ± 192.6 35.16 612.0 ± 176.6 28.86
AUC (μg.min/ml) 62.87 ± 15.77 25.09 64.47 ± 15.27 23.69 65.10 ± 14.33 22.01
λ (min−1) 0.0096 ± 0.0018 18.87 0.0088 ± 0.0020 22.54 0.0097 ± 0.0018 18.40
Vss/F (l) 0.1845 ± 0.0628 34.05 0.1929 ± 0.0521 27.04 0.1699 ± 0.0468 27.58
Cl/F (l/min) 0.0017 ± 0.0004 25.98 0.0016 ± 0.0004 23.89 0.0016 ± 0.0004 22.52
AUMC (μg.min2/ml) 7881.7 ± 2630.3 33.37 8313.7 ± 2284.4 27.48 8327.1 ± 2651.9 31.85
MRT (min) 125.1 ± 29.9 23.93 129.2 ± 21.7 16.78 126.6 ± 24.2 19.13
Cmin (ng/ml) 6.02 ± 3.41 56.70 6.31 ± 7.10 112.58 7.34 ± 7.98 108.71
t1/2λ (min) 75.2 ± 16.0 21.27 81.9 ± 15.3 18.70 74.0 ± 16.9 22.86
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concentration-time curves, and its frequency (40-45%)
was similar to that observed in this study. After Plantago
ovata husk administration, only 11% patients showed
more than one peak in the curve, while in the initial
situation the percentage was 44% and with placebo 50%.
So, it was proved that this fiber, Plantago ovata husk,
helps to maintain more stable levodopa concentrations,
a very important fact in Parkinson patients.
On the other hand, no significant differences were
found in total cholesterol, LDL-cholesterol and triglycer-
ides although the levels were slightly lower in the pres-
ence of Plantago ovata husk.
Other authors have demonstrated the beneficial effects
of fiber lowering cholesterol, triglycerides and glucose
[23-25]. Probably, we have not found a reduction in bio-
chemical parameters due to the short time of treatment
with fiber (14 days).Table 3 Pharmacokinetic parameters obtained alter the oral a
the three groups studied (initial situation; treatment with Pla
Parkinson patients
Initial situation Tr
Glucose (mg/100 ml) 105.50 ± 10.65
Urea (mg/100 ml) 42.96 ± 9.50
Creatinine (mg/100 ml) 0.89 ± 0.17
Tryglicerides (mg/100 ml) 94.83 ± 42.39
Total cholesterol (mg/100 ml) 214.39 ± 36.92
AST (GOT) (UI/l) 21.22 ± 4.49
ALT (GPT) (UI/l) 25.67 ± 8.98
Alkaline phosphatase (UI/l) 131.44 ± 43.91
GGT (UI/l) 17.06 ± 6.55
LDL (mg/100 ml) 135.18 ± 29.30
HDL (mg/100 ml) 60.17 ± 13.90When the data obtained for the three situations stud-
ied (initial situation, fiber administration and placebo ad-
ministration) are analyzed simultaneously, we can see
important inter- and intra-individual differences regard-
ing levodopa pharmacokinetics. For several volunteers,
the levodopa concentration-time curves are different on
day 0 (initial situation) and after placebo treatment,
showing important intra-individual differences. Al-
though levodopa kinetics was altered in the volunteers,
the study gives important information due to all pa-
tients received both treatments, and so, pharmacokin-
etics was followed in every patient. Knowledge of
individual patients’ levodopa behavior can contribute
to rationalize drug treatment according to disease pro-
gression [10].
In recent years, researchers’ attention has mainly fo-
cused on overcoming levodopa treatment complications
by optimizing drug pharmacokinetics [9,26].dministration of 100:25 mg/kg levodopa/carbidopa in
ntago ovata husk and treatment with placebo) to 18
eatment A (Plantago ovata husk) Treatment B (Placebo)
96.56 ± 10.62 98.06 ± 13.40
43.43 ± 11.76 45.93 ± 12.50
0.85 ± 0.15 0.86 ± 0.15
84.33 ± 29.28 94.11 ± 43.73
191.89 ± 27.73 209.50 ± 36.65
19.94 ± 4.47 20.33 ± 4.34
25.06 ± 9.51 26.00 ± 9.29
124.00 ± 40.68 126.00 ± 44.13
16.00 ± 6.15 19.85 ± 10.63
117.67 ± 22.23 132.32 ± 33.00
57.33 ± 15.91 58.33 ± 12.34
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clinical pharmacokinetics is important in rationalising
drug prescription at the start of the treatment but be-
comes essential with the advance of Parkinson’s disease
[27]. As the disease progresses, the synaptic dopamine con-
centrations and clinical effect become strictly dependent on
plasma levodopa concentrations, and the factors affecting
peripheral levodopa pharmacokinetics become critical to the
therapeutic response [9,28].
The levodopa plasma half-life is very short, resulting
in marked plasma drug concentration fluctuations which
are matched, as the disease progresses, with swings in
the therapeutic response (“wearing-off” phenomena).
“Wearing-off” phenomena can be also associated to the
more advanced disease stages with a “negative”, both
parkinsonism-exacerbating and dyskinetic effect of levo-
dopa at subtherapeutic plasma concentrations. Dyskinesias
may be also related to high-levodopa, excessive plasma
concentrations [9].
On the other hand, absorption of levodopa in the
proximal small intestine depends on gastric emptying,
which is erratic and may be slowed in Parkinson’s
disease.
In a study carried out by Djaldetti et al. in 1995 [29],
these authors concluded that “delayed-on” (prolonged
latencies to onset) phenomenon and “non-on” (treat-
ment failure) phenomenon are related to alterations of the
gastrointestinal transit time and absorption of levodopa.
Previous studies carried out in experimental animals
[30-33] showed that the administration of Plantago ovata
husk with levodopa/carbidopa treatment improved levo-
dopa pharmacokinetics. Fiber administration reduced the
maximum plasma concentrations (lower adverse effects)
and provided higher final concentrations (longer effect).
In the present study we have clearly demonstrated that
the fiber Plantago ovata husk contributed to obtain more
stable levodopa concentrations, with a reduction in the
number of patients with more than one peak in the
concentration-time curve. Plantago ovata husk administra-
tion caused a smoothing and homogenization of levodopa
absorption, providing more stable concentrations and final
higher levels, resulting in a great benefit for patients.
Taking into account the results obtained, and although
a long-term study may be carried out, it will be benefi-
cial for Parkinson patients to take Plantago ovata husk
with their usual levodopa treatment since the beginning
of the illness, in order to improve levodopa pharmaco-
kinetics and the response to this drug.
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